23ME-00610
23ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
OX2R <0.1 nM (Kd) |
IL-2 |
In Vitro
23ME-00610 binds to purified recombinant hCD200R1 isoforms and haplotypes with high affinity[1].
23ME-00610 (serial dilutions) binds to CD200R1 on the surface of primary CD4+ T cells with a mean EC50 of 0.34 nM; it binds to CD200R1 on the surface of CD8+ T cells with a representative EC50 of 0.32 nM; and it binds to CD200R1 on the surface of monocyte-derived dendritic cells with a mean EC50 of 0.55 nM[1].
23ME-00610 blocks the binding of CD200:CD200R1 in the ELISA system, with an IC50 value of 0.34 nM[1].
23ME-00610 (serial dilutions of 23ME-00610; 30 min) displaces pre-bound CD200 from U937 cells expressing CD200R1, with an EC50 value ranging from 0.32 to 1.04 nM[1].
Serial dilutions of 23ME-00610 inhibit CD200-induced recruitment of DOK2 to CD200R1 in the Jurkat reporter cell system, with a mean IC50 of 0.02 nM[1].
23ME-00610 (50 nM; 24 h for IL-2, 72 h for IFNγ) fully restores CD200-suppressed IL-2 production at a concentration of 50 nM in chronically stimulated primary CD3+ T cells, and restores CD200-suppressed IFNγ secretion with a mean EC50 of 0.055 nM[1].
23ME-00610 (0.08-20 nM; 120 h) enhances the killing effect of primary PBMCs on CD200-expressing COV-644-GFP ovarian cancer cells, with a mean EC50 of 2.09 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
Target
OX2R/CD200R1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)